Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice
- 1 August 1986
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 53 (2) , 245-251
- https://doi.org/10.1128/iai.53.2.245-251.1986
Abstract
The BALB/c mouse was selected as a model for infection with Brucella abortus on the basis of protracted nonclinical infection produced by strain 2308, virulent for cattle, and relatively rapid clearance of strain 19, an attenuated strain used to vaccinate cattle. Protection in mice vaccinated with strain 19 was compared with that obtained with nonliving vaccines at early (1 week) and later (4 weeks) intervals after challenge with strain 2308 and assessed by enumeration of B. abortus organisms in the spleen. Mice challenged 4 weeks after vaccination with strain 19 exhibited significant protection at 1 and 4 weeks postinfection (p.i.), with an increased magnitude of protection at the later time. When challenged 6 weeks after vaccination with strain 19, the level of protection diminished between 1 and 4 weeks p.i. and at the later time was not always significantly different from controls. Mice immunized 4 weeks earlier with nonliving vaccines in mineral oil with t trehalose dimycolate (TDM) and muramyl dipeptide (MDP) demonstrated patterns of protection similar to those obtained following the 6 week vaccination-challenge interval with strain 19. Vaccination with cell envelopes derived from strain 2308 produced equivalent protection at 1 week p.i. whether administered in phosphate-buffered saline, incomplete Freund adjuvant, or the TDM and MDP adjuvant. Equivalent protection also followed vaccination with strain 2308 killed whole cells, cell envelopes, or outer membrane proteins in phosphate-buffered saline or in the TDM and MDP adjuvant. The TDM and MDP adjuvant alone induced nonspecific resistance, which peaked at 1 day p.i. and was still present at 1 week p.i., although by this time its magnitude was significantly less than the protection induced by antigen combined with the adjuvant. These data, together with the results of antibody assays and passive and adoptive transfer studies, suggested that protection at 1 week p.i. could be accounted for largely by an effect of O antibodies, with T cell-mediated immune responses having a subsidiary role.This publication has 30 references indexed in Scilit:
- Immunity to Infection with Salmonella typhimurium: Mouse-Strain Differences in Vaccine- and Serum-Mediated ProtectionThe Journal of Infectious Diseases, 1984
- Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients.The Journal of Experimental Medicine, 1983
- Resistance and Susceptibility of Mice to Bacterial Infection. IV. Genetic and Cellular Basis of Resistance to Chronic Infection with Brucella abortusThe Journal of Infectious Diseases, 1982
- In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infectionCellular Immunology, 1982
- Synthetic immunostimulants derived from the bacterial cell wallJournal of Medicinal Chemistry, 1980
- Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.Proceedings of the National Academy of Sciences, 1977
- Enhancement of Nonspecific Immunity to Bacterial Infection by Cord Factor (6,6'MTrehalose Dimycolate)The Journal of Infectious Diseases, 1977
- Mechanism of Immunity Against BrucellaNature, 1965
- THE PASSIVE TRANSFER OF ACQUIRED RESISTANCE TO LISTERIA MONOCYTOGENESThe Journal of Experimental Medicine, 1964
- THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCEThe Journal of Experimental Medicine, 1964